تجاوز إلى المحتوى الرئيسي
User Image

ا.د. عايدة عبد الحميد قريش Prof. Aida Abdelhamid Korish

Professor

Professor of Physiology College of Medicine

كلية الطب
مبني 11- كلية الطب البشري- الدور الثاني مكتب رقم 106
المنشورات
مقال فى مجلة
2021

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet- Induced Nonalcoholic Fatty Liver Disease

Camel milk (CM) has a unique composition rich in antioxidants, trace elements, immunoglobulins, insulin, and insulin-like
proteins. Treatment by CM demonstrated protective effects against nonalcoholic fatty liver disease (NAFLD) induced by a highfat
cholesterol-rich diet (HFD-C) in rats. CM dampened the steatosis, inflammation, and ballooning degeneration of the
hepatocytes. It also counteracted hyperlipidemia, insulin resistance (IR), glucose intolerance, and oxidative stress. The
commencement of NAFLD triggered the peroxisome proliferator-activated receptor-α (PPAR-α), carnitine palmitoyltransferase-
1 (CPT1A), and fatty acid-binding protein-1 (FABP1) and decreased the PPAR-γ expression in the tissues of the
animals on HFD-C. This was associated with increased levels of the inflammatory cytokines IL-6 and TNF-α and leptin and
declined levels of the anti-inflammatory adiponectin. Camel milk treatment to the NAFLD animals remarkably upregulated
PPARs (α, γ) and the downstream enzyme CPT1A in the metabolically active tissues involved in cellular uptake and betaoxidation
of fatty acids. The enhanced lipid metabolism in the CM-treated animals was linked with decreased expression of
FABP1 and suppression of IL-6, TNF-α, and leptin release with augmented adiponectin production. The protective effects of
CM against the histological and biochemical features of NAFLD are at least in part related to the activation of the hepatic and
extrahepatic PPARs (α, γ) with consequent activation of the downstream enzymes involved in fat metabolism. Camel milk
treatment carries a promising therapeutic potential to NAFLD through stimulating PPARs actions on fat metabolism and
glucose homeostasis. This can protect against hepatic steatosis, IR, and diabetes mellitus in high-risk obese patients.

نوع عمل المنشور
Original article
اسم الناشر
Hindawi
مجلة/صحيفة
PPAR Research
مزيد من المنشورات
publications

ABSTRACT
Methotrexate (MTX) is widely used chemotherapeutic and immune suppressant agent. Hepatotoxicity is
a common side effect of chronic MTX therapy. This study investigated the…

بواسطة Abeer Khalid Al-Ghumlas, Manan A. Alhakbany & Aida A. Korish
2023
تم النشر فى:
Taylor& Francis
publications

Camel milk (CM) has a unique composition rich in antioxidants, trace elements, immunoglobulins, insulin, and insulin-like
proteins. Treatment by CM demonstrated protective effects against…

بواسطة Haifa M. AlNafea and Aida A. Korish
2021
تم النشر فى:
Hindawi